Quick Answer
Opus Genetics, Inc. reported Diluted EPS of $0.80 per share (loss) for fiscal year 2025.
Opus Genetics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.80 | +62.8% |
| 2024 | -$2.15 | -367.4% |
| 2023 | -$0.46 | -152.9% |
| 2022 | $0.87 | +122.8% |
| 2021 | -$3.82 | +27.7% |
| 2020 | -$5.28 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.25 | +13.8% | -108.3% |
| June 30, 2025 | -$0.12 | +60.0% | +50.0% |
| March 31, 2025 | -$0.24 | +17.2% | +17.2% |
| September 30, 2024 | -$0.29 | -216.0% | +3.3% |
| June 30, 2024 | -$0.30 | -25.0% | -3.4% |
| March 31, 2024 | -$0.29 | -3.6% | -216.0% |
| September 30, 2023 | $0.25 | +213.6% | +204.2% |
| June 30, 2023 | -$0.24 | +4.0% | +14.3% |
- Opus Genetics, Inc. showed an increase of +62.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2020–2025 period, Opus Genetics, Inc.’s diluted eps has grown by 84.8% (from $5.28 per share (loss) to $0.80 per share (loss)).
- The most recent figure is from Opus Genetics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: